The One Drop diabetes management platform has agreed to integrate MannKind’s BluHale inhaler monitoring device for the Afrezza insulin DPI, the companies said. The integration of the BluHale device will allow for monitoring of insulin doses, glucose forecasts, and other services for patients using the Afrezza inhaler.
MannKind Corporation CEO Michael Castagna said, “Earlier this year, One Drop announced clinical data that demonstrated using Afrezza with One Drop provided a significant improvement in A1C levels. We now look forward to integrating automatic dose detection into their platform in order to further evolve the patient experience. We believe the future of diabetes management will increasingly depend on data collected on a smartphone that provides real time decision support insights that will help patients and providers achieve improved outcomes.”
One Drop CEO Jeff Dachis added, “For too long, people with diabetes have been trying to make decisions about what to do and when to do it by looking in the rear-view mirror. Having automated dose detection with Afrezza will be a huge step forward in helping to remove burden from people’s care regimen, and will enable powerful, data-driven insights, potentially leading to even better patient health outcomes.”
In January 2019, MannKind introduced a direct purchase program for Afrezza in the US. Afrezza was approved by the FDA in June 2014.
Read the MannKind Corporation and One Drop press release.
